Quick Summary
• German medical startup BellaSeno has enrolled 30 patients across two Australian trials of a polycaprolactone breast scaffold designed to regenerate tissue without leaving a permanent foreign body. The 30 patients are spread across a first-in-human safety study that ran from 2021 to 2023 and enrolled 19 patients, and a pivotal trial launched in January 2026…
Additional Context
German medical startup BellaSeno has enrolled 30 patients across two Australian trials of a polycaprolactone breast scaffold designed to regenerate tissue without leaving a permanent foreign body.
The 30 patients are spread across a first-in-human safety study that ran from 2021 to 2023 and enrolled 19 patients, and a pivotal trial launched in January 2026 in which 11 patients have so far undergone surgery, with more enrolled. The company expects the total patient count to exceed 60 by the end of August.
“Clinicians who are looking at MRI scans in these patients a few years after receiving these scaffolds would say they were simply looking at normal breast tissue,” Professor Anand Deva said.
3D printed resorbable breast implant. Image via BellaSeno.
Early Trial Shows Promising Results